National Cancer Research Center and Boehringer Ingelheim Japan sign comprehensive alliance agreement.

The purpose of this 3 year contract is to establish a cooperative system concerning Boehringer-Ingelheim’s newly developed antitumor drugs with the National Cancer Research Center so that clinical development in Japan can be undertaken early. Drug discovery using the seeds of the National Cancer Research Center it is not included in the partnership.

Boehringer Ingelheim Japan news release, July 11, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny